Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

Combining reduced-dose olaparib with radium-223 improved rPFS in mCRPC patients, especially those without prior docetaxel and limited bone metastases. The combination's efficacy is based on mechanisms ...

The forum highlighted advancements in bladder cancer treatment, focusing on intravesical therapies, systemic immunotherapy, and clinical trials for NMIBC and MIBC. Integration of PD-1 inhibitors with ...

Enzalutamide plus ADT significantly improves 5-year overall survival in mHSPC, with a 30% reduction in death risk compared to placebo plus ADT. The survival benefit of enzalutamide is consistent ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Dr Shore discussed the potential for ultra-low PSA response to serve as an end point in future clinical trials. He highlighted how this metric could potentially influence precision medicine approaches ...

"CAN-2409 immunotherapy could represent the first new therapy for men with localized prostate cancer in over 20 years," wrote the authors. Adding aglatimagene besadenovec (CAN-2409) to standard of ...

Darolutamide showed modest efficacy in mCRPC patients post-ARPI treatment, with varying clinical benefit rates across molecularly defined cohorts. Higher clinical benefit rates were observed in ...

Dr Murray on pembrolizumab counseling: “I split treatments into those we continue to put inside your bladder that patients are familiar with, and then pembrolizumab, which is FDA approved but ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.